Tagged nafld
Press Release
PharmaNest Announces New Pre-Clinical NASH and Clinical Liver Cancer Data to Be Presented at the AASLD | the Liver Meeting Digital ExperienceTM (TLMdX) 2020
New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and regression of Fibrosis in human in-vitro 3D NASH Spheroid models and for the automated classification of post-transplant patients in F4 Fibrosis Stage with and without Hepatocellular carcinoma (HCC) at the Liver Meeting Digital Experience 2020 Read More
Press Release
PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the EASL | Digital International Liver Congress 2020
New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in pre-clinical tissues and adult NASH biopsies at the Digital International Liver CongressTM 2020 Read More
Press Release
PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019
New image analysis data of biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in both adult and pediatric cohorts at the Liver Meeting® 2019. Read More
Press Release
PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH
FibroNest cloud-based image analysis tool provides the most advanced phenotypic image analysis and translational platform for the automated quantification of fibrosis and steatosis for NASH and for other fibrotic conditions in drug discovery and drug development projects. Read More
Press Release